What is the equity of PharmaResearch Co this year?
PharmaResearch Co has equity of 433.1 B KRW this year.
In 2024, PharmaResearch Co's equity was 433.1 B KRW, a 26.08% increase from the 343.5 B KRW equity in the previous year.
PharmaResearch Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding PharmaResearch Co's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating PharmaResearch Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
PharmaResearch Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in PharmaResearch Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
PharmaResearch Co has equity of 433.1 B KRW this year.
The equity of PharmaResearch Co has increased/decreased by 26.08% increased compared to the previous year.
A high equity is advantageous for investors of PharmaResearch Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of PharmaResearch Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of PharmaResearch Co can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of PharmaResearch Co can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of PharmaResearch Co include profits, dividend payments, capital increases, and acquisitions.
The equity of PharmaResearch Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, PharmaResearch Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, PharmaResearch Co paid a dividend of 950 KRW . This corresponds to a dividend yield of about 0.49 %. For the coming 12 months, PharmaResearch Co is expected to pay a dividend of 1,044.52 KRW.
The current dividend yield of PharmaResearch Co is 0.49 %.
PharmaResearch Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.
PharmaResearch Co paid dividends every year for the past 12 years.
For the upcoming 12 months, dividends amounting to 1,044.52 KRW are expected. This corresponds to a dividend yield of 0.54 %.
PharmaResearch Co is assigned to the 'Health' sector.
To receive the latest dividend of PharmaResearch Co from 4/18/2024 amounting to 950 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.
The last dividend was paid out on 4/18/2024.
In the year 2023, PharmaResearch Co distributed 660 KRW as dividends.
The dividends of PharmaResearch Co are distributed in KRW.
Our stock analysis for PharmaResearch Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaResearch Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.